Combination venetoclax and olverembatinib (HQP1351) as a successful therapeutic strategy for relapsed/refractory (R/R) mixed-phenotype blast phase of chronic myeloid leukemia

被引：2

作者：

Zhang, Tongtong ^{[1
,2
]}

Zhou, Haixia ^{[1
,2
]}

Xu, Mingzhu ^{[1
,2
]}

Qian, Chongsheng ^{[1
,2
]}

Sun, Aining ^{[1
,2
]}

Wu, Depei ^{[1
,2
]}

Xue, Shengli ^{[1
,2
]}

机构：

[1] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Hematol, Natl Clin Res Ctr Hematol Dis, Suzhou 215000, Peoples R China

[2] Soochow Univ, Inst Blood & Marrow Transplantat, Collaborat Innovat Ctr Hematol, Suzhou 215000, Peoples R China

来源：

ANNALS OF HEMATOLOGY | 2023年 / 102卷 / 04期

基金：

中国国家自然科学基金;

关键词：

D O I：

10.1007/s00277-023-05110-y

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：973 / 975

页数：3

共 50 条

[21] Dose-Reduced FLA-IDA in Combination with Venetoclax Is an Effective and Safe Salvage Therapy in Relapsed and Refractory Acute Myeloid Leukemia (R/R AML)
Schoenrock, Martin
Sonnemann, Piet
Michalowski, Nina
Heuser, Michael
Thol, Felicitas
Ayuk, Francis Ayuketang
Wolschke, Christine
Klyuchnikov, Evgeny
Bokemeyer, Carsten
Fiedler, Walter
Cichutek, Sophia
CANCERS, 2024, 16 (22)
[22] A Phase 2 Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter's Syndrome (RS)
Crombie, Jennifer L.
Ryan, Christine E.
Ren, Yue
Tyekucheva, Svitlana
Carey, Celeste
Zou, Aaron
Normilus, Samantha
Montegaard, Josie
Soumerai, Jacob D.
Bhandari, Shruti
Arnason, Jon E.
Alencar, Alvaro J.
Kim, Austin I.
Parry, Erin M.
Armand, Philippe
Fisher, David C.
Brown, Jennifer R.
Davids, Matthew S.
BLOOD, 2024, 144 : 4628 - 4629
[23] Subgroup analysis from a phase II trial of ponatinib and blinatumomab in relapsed/refractory (R/R) Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia in lymphoid blast phase
Zoghbi, Marianne
Jabbour, Elias
Haddad, Fadi
Short, Nicholas James
Nasnas, Cedric Christophe
Macaron, Walid
Nasr, Lewis Fady
Jain, Nitin
Montalban-Bravo, Guillermo
Kadia, Tapan M.
Daver, Naval Guastad
Chien, Kelly Sharon
Valero, Yesid Alvarado
Issa, Ghayas C.
Mayor, Ejiroghene
Deen, Wuliamatu
Thankachan, Jennifer
Garris, Rebecca
Ravandi, Farhad
Kantarjian, Hagop M.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[24] Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
Qian Jiang
Zongru Li
Yazhen Qin
Weiming Li
Na Xu
Bingcheng Liu
Yanli Zhang
Li Meng
Huanling Zhu
Xin Du
Suning Chen
Yang Liang
Yu Hu
Xiaoli Liu
Yongping Song
Lichuang Men
Zi Chen
Qian Niu
Hengbang Wang
Ming Lu
Dajun Yang
Yifan Zhai
Xiaojun Huang
Journal of Hematology & Oncology, 16
[25] Tuspetinib Myeloid Kinase Inhibitor Safety and Efficacy As Monotherapy and Combined with Venetoclax in Phase 1/2 Trial of Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)
Daver, Naval
Lee, Kyoo Hyung
Choi, Yunsuk
Jonas, Brian A.
Arellano, Martha
Koller, Paul B.
Jung, Chul W.
Sohn, Sang Kyun
Fathi, Amir T.
Lee, Jeong-Ok
Yoon, Sung-Soo
Watts, Justin M.
Vachhani, Pankit
Shin, Ho-Jin
Hu, Jia
Sinha, Ranjeet
Khan, Nawazish
Rice, William G.
Bejar, Rafael
BLOOD, 2023, 142
[26] Novel BCR-ABL1 Tyrosine Kinase Inhibitor (TKI) HQP1351 (Olverembatinib) Is Efficacious and Well Tolerated in Patients with T315I-Mutated Chronic Myeloid Leukemia (CML): Results of Pivotal (Phase II) Trials
Jiang, Qian
Huang, Xiaojun
Chen, Zi
Niu, Qian
Shi, Dayu
Li, Zongru
Hou, Yue
Hu, Yu
Li, Weiming
Liu, Xiaoli
Xu, Na
Song, Yongping
Zhang, Yanli
Meng, Li
Hong, Zhenya
Liu, Bingcheng
Zeng, Shan
Men, Lichuang
Li, Yan
Chen, Suning
Xue, Mengxing
Zhu, Huanling
Li, He
Du, Xin
Lou, Jin
Zhang, Xiaohan
Liang, Yang
Dai, Yujun
Lu, Ming
Wang, Hengbang
Ji, Jiao
Yue, Changai
Yang, Dajun
Zhai, Yifan
BLOOD, 2020, 136
[27] Overcoming Venetoclax (Ven) Resistance through Glutamine (Gln) Depletion: Final Analysis of the Phase 1 Trial of Ven and Pegcrisantaspase (PegC) Combination in Relapsed and Refractory (R/R) Acute Myeloid Leukemia (AML)
Liu, Yuchen
Bollino, Dominique
Bah, Osman M.
Strovel, Erin T.
Zarrabi, Jinoos
Philip, Sunita
Mostafa, Ezzat
Lapidus, Rena G.
Baer, Maria R.
Niyongere, Sandrine
Duong, Vu H.
Dougherty, Christine C.
Caprinolo, Katherine
Emadi, Ashkan
BLOOD, 2023, 142
[28] MURANO Trial Establishes Feasibility of Time-Limited Venetoclax-Rituximab (VenR) Combination Therapy in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
Seymour, John F.
Kipps, Thomas J.
Eichhorst, Barbara
Hillmen, Peter
D'Rozario, James
Assouline, Sarit
Owen, Carolyn
Robak, Tadeusz
de la Serna, Javier
Jaeger, Ulrich
Cartron, Guillaume
Montillo, Marco
Lamanna, Nicole
Verdugo, Maria E.
Punnoose, Elizabeth A.
Jiang, Yanwen
Wang, Jue
Boyer, Michelle
Humphrey, Kathryn
Mobasher, Mehrdad
Kater, Arnon P.
BLOOD, 2018, 132
[29] Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP) with T315I Mutation
Jiang, Qian
Li, Zongru
Hou, Yue
Hu, Yu
Li, Weiming
Liu, Xiaoli
Xu, Na
Zhang, Yanli
Song, Yongping
Meng, Li
Hong, Zhenya
Liu, Bingcheng
Li, Yan
Chen, Suning
Xue, Mengxing
Zhu, Huanling
Li, He
Du, Xin
Lou, Jin
Zhang, Xiaohan
Liang, Yang
Dai, Yu-Jun
Chen, Zi
Niu, Qian
Men, Lichuang
Yang, Dajun
Zhai, Yifan
Huang, Xiao-Jun
BLOOD, 2022, 140
[30] Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial (vol 15, 113, 2022)
Jiang, Qian
Li, Zongru
Qin, Yazhen
Li, Weiming
Xu, Na
Liu, Bingcheng
Zhang, Yanli
Meng, Li
Zhu, Huanling
Du, Xin
Chen, Suning
Liang, Yang
Hu, Yu
Liu, Xiaoli
Song, Yongping
Men, Lichuang
Chen, Zi
Niu, Qian
Wang, Hengbang
Lu, Ming
Yang, Dajun
Zhai, Yifan
Huang, Xiaojun
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)

← 1 2 3 4 5 →